Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has seen a stock price increase of over 6% following the approval of its innovative drug, Ologliptin capsules, by the National Medical Products Administration for the treatment of type 2 diabetes [1] Group 1: Drug Approval - The innovative drug Ologliptin capsules have been approved for use as a monotherapy or in combination with Metformin to improve blood sugar control in adult patients with type 2 diabetes [1] - The approval marks a significant step for Dongyang Sunshine Pharmaceutical in its long-term management of chronic diseases [1] Group 2: AI Strategy - Dongyang Sunshine Pharmaceutical is deepening its AI strategic layout by launching an AI intelligent research and development platform focused on the PROTAC mechanism [1] - The platform aims to achieve a comprehensive and systematic data foundation for AI-driven rational design of PROTAC lead compounds, significantly surpassing existing public databases in data scale and structural granularity [1] - This initiative is expected to accelerate the rational design and clinical translation of PROTAC lead compounds [1]